CDK5R1 Antibody

What is CDK5R1 and why is it significant in neurodevelopmental research?

CDK5R1 (cyclin-dependent kinase 5, regulatory subunit 1) encodes the p35 protein, which serves as the primary activator of CDK5. This gene-protein system plays fundamental roles in central nervous system (CNS) development and function. Its significance stems from substantial evidence linking mutations in CDK5R1 to various neurodevelopmental disorders, particularly non-syndromic intellectual disability (NS-ID) . Research indicates that CDK5R1 post-transcriptional regulation is critical for proper CNS development, making it an important target for investigators studying neurological conditions .

How do CDK5 and CDK5R1 interact functionally in neuronal systems?

CDK5R1 produces p35, which binds to and activates CDK5 in a mechanism distinct from other cyclin-dependent kinases. The p35 protein can undergo cleavage by calpain (a calcium-dependent protease) to generate p25, which affects CDK5 regulation . Proper p35 cleavage is essential for normal cellular function, as evidenced by the functional characterization of the CDK5R1 p.A108V mutation, which demonstrates impaired p35 cleavage by calpain . This interaction is particularly important in neurons where CDK5/p35 complexes regulate cytoskeletal dynamics, synaptic plasticity, and neuronal migration during development.

What role does CDK5R1 play in pathological conditions beyond neurological disorders?

While CDK5R1 is prominently linked to neurological conditions, research suggests its involvement in other pathological conditions. The gene's expression pattern and regulatory function extend to cellular processes implicated in cancer progression, particularly in triple-negative breast cancer (TNBC) where CDK5 inhibition has been studied . The multifunctional nature of CDK5R1 makes it relevant to diverse research fields, from neurodevelopment to oncology, warranting investigation using specific antibodies to elucidate its varied roles in different tissues and disease states.

How should researchers select the most suitable CDK5R1 antibody for specific experimental applications?

Selection of an appropriate CDK5R1 antibody should be guided by several factors:

• Experimental application: Different applications require antibodies with specific properties:

  • Western blot: High specificity antibodies with minimal cross-reactivity

  • IHC/IF: Antibodies validated for spatial protein localization

  • ELISA: Antibodies with appropriate epitope exposure in native conditions

  • IP: Antibodies capable of binding the native protein in solution

• Species reactivity: Match the antibody's reactivity to your experimental model (human, mouse, rat)

• Clonality considerations:

  • Monoclonal: Higher specificity, consistent lot-to-lot reproducibility

  • Polyclonal: Generally higher sensitivity, recognition of multiple epitopes

• Validation data: Prioritize antibodies with experimental validation data in applications matching your intended use

What controls are essential when using CDK5R1 antibodies for protein detection methods?

For rigorous CDK5R1 antibody-based experiments, the following controls are critical:

• Positive controls: Tissues or cell lines with confirmed CDK5R1 expression (e.g., neuronal cells for p35 detection)

• Negative controls:

  • Primary antibody omission

  • Isotype controls matching the primary antibody's host species and isotype

  • Tissues/cells with confirmed CDK5R1 absence or knockdown

• Specificity controls:

  • Blocking peptide competition assays

  • siRNA/shRNA knockdown validation

  • CDK5R1-null cells (if available)

• Loading/normalization controls: Appropriate housekeeping proteins depending on your experimental system and question

Implementation of these controls helps distinguish specific signal from background and validates antibody specificity, particularly important given potential cross-reactivity with related proteins in the CDK family.

How do CDK5R1 antibody applications differ between human and animal model research?

CDK5R1 antibody applications vary between human and animal model research in several important ways:

• Epitope conservation: While CDK5R1 is relatively conserved, species-specific differences in certain epitopes may affect antibody cross-reactivity. Select antibodies validated across species of interest .

• Tissue preparation methodologies: Different fixation protocols may be optimal for different species:

  • Human tissues often require longer fixation times

  • Rodent tissues may require specific antigen retrieval methods

• Background considerations:

  • Human tissues often exhibit higher autofluorescence

  • Mouse tissues may show different non-specific binding patterns

• Validation standards: For translational research, antibodies should be validated in both human and animal models to confirm comparable detection of homologous proteins .

The available CDK5R1 antibodies include options reactive with human, mouse, or rat proteins, with some offering multi-species reactivity that facilitates translational research between animal models and human studies .

What are the optimal conditions for immunoprecipitation of CDK5R1 and its binding partners?

Optimal immunoprecipitation (IP) of CDK5R1 and its interaction partners requires:

• Lysis buffer selection:

  • For CDK5-p35 complex preservation: HEPES-based buffers (pH 7.4) with 0.5-1% NP-40 or Triton X-100

  • Include protease inhibitors to prevent p35 degradation

  • Add phosphatase inhibitors to maintain phosphorylation states

• Antibody selection:

  • Choose antibodies specifically validated for IP applications

  • Consider epitope accessibility in the native protein

  • For co-IP of CDK5/p35 complex, ensure the epitope doesn't interfere with the interaction surface

• Protocol optimization:

  • Pre-clear lysates to reduce non-specific binding

  • Optimize antibody concentration (typically 2-5 μg per 500 μg protein)

  • Extended incubation (overnight at 4°C) may improve complex recovery

  • Gentle washing to preserve protein-protein interactions

• Verification approaches:

  • Reciprocal IP (IP with anti-CDK5 followed by p35 detection and vice versa)

  • Include negative controls (isotype-matched antibodies)

  • Confirm specificity with competing peptides

This approach allows for reliable investigation of CDK5R1's interactome, including its primary binding partner CDK5 and potential novel interaction partners.

How should researchers approach Western blot optimization for detecting both full-length p35 and its cleaved product p25?

Optimizing Western blot detection of both p35 (full-length) and p25 (cleaved product) requires careful consideration of:

• Sample preparation:

  • Fresh preparation with protease inhibitors to prevent artificial p35 cleavage

  • Consider phosphatase inhibitors as phosphorylation may affect antibody recognition

  • Rapid processing at cold temperatures to minimize ex vivo cleavage

• Gel selection and separation:

  • 12-15% acrylamide gels for optimal resolution between p35 (35 kDa) and p25 (25 kDa)

  • Consider gradient gels (4-20%) for simultaneous detection of CDK5 and p35/p25

• Antibody selection:

  • Choose antibodies recognizing epitopes present in both p35 and p25

  • Alternatively, use separate antibodies specific to each form

  • N-terminal specific antibodies will detect only p35, while C-terminal antibodies detect both

• Detection optimization:

  • Enhanced chemiluminescence (ECL) or fluorescence-based detection

  • Sequential probing may be necessary if using multiple antibodies

  • Appropriate exposure times to capture both high-abundance and low-abundance forms

• Quantification considerations:

  • Calculate p25/p35 ratio to assess calpain-mediated cleavage

  • Normalize to appropriate loading controls

  • Consider the physiological context, as p25 levels increase in certain pathological conditions

This methodology enables accurate assessment of CDK5R1 processing, which is particularly relevant given that the p.A108V mutation identified in NS-ID patients shows impaired p35 cleavage by calpain .

What methods are recommended for studying the post-transcriptional regulation of CDK5R1 expression?

The post-transcriptional regulation of CDK5R1 expression can be studied through:

• 3′-UTR reporter assays:

  • Construct luciferase reporters containing wild-type or mutant CDK5R1 3′-UTR sequences

  • Compare expression levels between constructs to identify regulatory elements

  • This approach revealed that mutations in CDK5R1 3′-UTR altered gene expression levels

• RNA-protein binding studies:

  • RNA immunoprecipitation (RIP) to identify proteins binding to CDK5R1 mRNA

  • RNA electrophoretic mobility shift assay (REMSA) to confirm direct interactions

  • Cross-linking immunoprecipitation (CLIP) for in vivo binding site identification

  • These techniques have shown that CDK5R1 3′-UTR interacts with nELAV and hnRNPA2/B1 RNA-binding proteins

• MicroRNA regulatory studies:

  • Bioinformatic prediction of miRNA binding sites in CDK5R1 3′-UTR

  • Luciferase assays with miRNA mimics/inhibitors

  • Ago-CLIP to identify miRNA-mRNA interactions

  • miR-103/107 has been shown to regulate CDK5R1 expression

• mRNA stability and decay assessment:

  • Actinomycin D chase experiments to measure mRNA half-life

  • Polysome profiling to assess translation efficiency

  • These approaches can determine how 3′-UTR variations affect mRNA stability and translation

These methodologies have revealed the importance of CDK5R1 3′-UTR in post-transcriptional regulation, supporting the relevance of 3′-UTR mutations found in NS-ID patients .

How can researchers accurately assess the specificity of CDK5R1 antibodies in the context of related CDK family proteins?

Assessing CDK5R1 antibody specificity requires systematic approaches:

• Sequence comparison analysis:

  • Perform epitope mapping against related proteins

  • Identify regions of high homology between CDK5R1 and other CDK regulators

  • Use this information to select antibodies targeting unique regions

• Overexpression controls:

  • Test antibody reactivity in cells overexpressing CDK5R1

  • Compare with cells overexpressing related proteins (CDK5R2/p39)

  • Ideal antibodies should show signal proportional to expression level in CDK5R1 transfectants only

• Knockout/knockdown validation:

  • Test antibodies in CDK5R1 knockout/knockdown models

  • Complete signal elimination confirms specificity

  • Persistent signal suggests cross-reactivity with related proteins

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Specific signals should be eliminated

  • Perform with peptides from related proteins to identify cross-reactivity

• Immunoprecipitation-mass spectrometry:

  • Perform IP followed by mass spectrometry

  • Identify all proteins captured by the antibody

  • Determines specificity by identifying unintended targets

This comprehensive validation is essential because the CDK family contains multiple related proteins with structural similarities that could lead to cross-reactivity.

What approaches can resolve contradictory findings when studying CDK5R1 expression in different experimental models?

Resolving contradictory findings in CDK5R1 expression studies requires:

• Methodological standardization:

  • Compare antibody clones used across studies

  • Standardize detection methods (e.g., chemiluminescence vs. fluorescence)

  • Establish consistent sample preparation protocols

  • Create reference standards for quantification

• Context-dependent expression analysis:

  • Characterize cell/tissue-specific expression patterns

  • Assess developmental stage-specific expression

  • Evaluate the impact of physiological/pathological conditions

  • Document experimental conditions that may influence expression

• Isoform-specific detection:

  • Develop methods to distinguish potential isoforms

  • Use multiple antibodies targeting different epitopes

  • Complement protein studies with transcript analysis

  • Consider post-translational modifications that affect detection

• Meta-analysis approaches:

  • Systematically compare methodologies across contradictory studies

  • Identify patterns explaining divergent results

  • Propose unified models incorporating contextual differences

  • Design experiments specifically addressing contradictions

This systematic approach helps reconcile apparently contradictory findings by identifying experimental variables that may influence CDK5R1 detection and distinguishing genuine biological differences from technical artifacts.

How can researchers integrate CDK5R1 genetic variant data with functional antibody-based studies?

Integrating CDK5R1 genetic variant data with functional antibody studies requires:

• Variant-specific antibody approaches:

  • Develop antibodies specific to common CDK5R1 variants

  • Use epitope-specific antibodies that can distinguish variant forms

  • Employ phospho-specific antibodies for variants affecting phosphorylation sites

• Expression system comparisons:

  • Generate isogenic cell lines expressing wild-type vs. variant CDK5R1

  • Use antibodies to compare expression levels, localization, and stability

  • This approach helped characterize the functional impact of p.A108V mutation on p35 cleavage

• Patient-derived material analysis:

  • Apply validated antibodies to patient samples with known CDK5R1 variants

  • Compare protein expression patterns with genotypic data

  • Correlate antibody-detected alterations with clinical phenotypes

• Structural-functional correlations:

  • Predict variant effects on protein structure

  • Use antibodies recognizing conformation-specific epitopes

  • Determine how variants affect protein-protein interactions

• Statistical approaches for genotype-phenotype correlations:

  • Integrate antibody-based quantitative data with genetic information

  • Apply statistical methods like Odds Ratio (OR) calculation

  • This approach revealed that the rs735555:C>T polymorphism was associated with increased risk for NS-ID

This integrative approach provides mechanistic insights into how genetic variations, like those in the CDK5R1 3′-UTR, functionally impact gene expression and contribute to disease phenotypes .

How might single-cell analysis techniques advance our understanding of CDK5R1 expression heterogeneity?

Single-cell analysis techniques offer transformative potential for understanding CDK5R1 expression:

• Single-cell immunofluorescence approaches:

  • Multiplex IF using CDK5R1 antibodies with cell-type markers

  • Quantitative analysis of expression levels in individual cells

  • Spatial context preservation within tissues

  • Correlation with activation/differentiation states

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated CDK5R1 antibodies for high-dimensional analysis

  • Simultaneous detection of dozens of proteins alongside CDK5R1

  • Identification of rare cell populations with unique CDK5R1 expression

  • Clustering algorithms to define expression patterns

• Single-cell Western blotting:

  • Microfluidic platforms for protein analysis in individual cells

  • Quantification of p35/p25 ratios at single-cell resolution

  • Detection of cell-to-cell variability in post-translational modifications

  • Correlation with functional cellular states

• Integration with single-cell transcriptomics:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing)

  • Correlation between CDK5R1 protein and mRNA levels

  • Identification of regulatory networks at single-cell resolution

  • Discovery of cell-state-specific post-transcriptional regulation

These approaches would reveal how CDK5R1 expression varies across cell types and states, potentially uncovering cell-specific roles in both normal development and pathological conditions like intellectual disability .

What novel antibody-based technologies are emerging for studying CDK5R1 dynamics in live cells?

Emerging antibody-based technologies for studying CDK5R1 dynamics include:

• Intrabodies and nanobodies:

  • Genetically encoded antibody fragments expressed intracellularly

  • Fusion with fluorescent proteins for real-time CDK5R1 visualization

  • Monitoring of CDK5R1 localization during neuronal development

  • Observation of p35 to p25 conversion in response to stimuli

• FRET-based biosensors:

  • Förster resonance energy transfer pairs to monitor CDK5-p35 interaction

  • Real-time visualization of complex formation and dissociation

  • Spatial mapping of CDK5 activation in subcellular compartments

  • Quantitative measurement of activation kinetics

• Antibody-based optogenetic tools:

  • Light-controllable antibody fragments targeting CDK5R1

  • Spatiotemporal control of CDK5R1 function in specific regions

  • Examination of local CDK5 activation consequences

  • Integration with live imaging for function-structure correlations

• Bioluminescence resonance energy transfer (BRET):

  • Luciferase-antibody fusions for energy transfer to fluorophore-tagged CDK5R1

  • Reduced phototoxicity compared to fluorescence methods

  • Suitable for long-term imaging of CDK5R1 dynamics

  • Quantitative measurement of protein interactions

These technologies would transform our understanding of CDK5R1 dynamics, especially regarding the spatial and temporal regulation of CDK5 activity through p35/p25 in developing neurons and in disease contexts.

How can systems biology approaches integrate CDK5R1 antibody-based proteomic data with other -omics datasets?

Systems biology integration of CDK5R1 antibody-based proteomic data involves:

• Multi-omics data integration frameworks:

  • Correlation of CDK5R1 protein levels (antibody-based) with transcriptomic data

  • Integration with phosphoproteomic data to map CDK5 substrate networks

  • Incorporation of genetic variation data, especially 3′-UTR polymorphisms

  • Network analysis to identify regulatory hubs

• Pathway enrichment methodologies:

  • CDK5R1 interactome mapping using antibody-based proteomics

  • Functional annotation of interacting partners

  • Identification of enriched pathways and processes

  • Visualization of CDK5R1 in the context of cellular signaling networks

• Mathematical modeling approaches:

  • Ordinary differential equation models of CDK5-p35-p25 dynamics

  • Parameter estimation using quantitative antibody-based data

  • Sensitivity analysis to identify critical regulatory nodes

  • Prediction of system responses to perturbations

• Machine learning integration:

  • Supervised learning to classify cell states based on CDK5R1 expression patterns

  • Feature extraction from antibody-based imaging data

  • Prediction of functional outcomes from molecular signatures

  • Identification of biomarker signatures for neurological disorders

These integrative approaches would position CDK5R1 within broader cellular networks, providing context for how genetic variations, like the rs735555:C>T polymorphism associated with NS-ID , propagate through molecular networks to affect cellular function and ultimately cause disease.

What are the common pitfalls in CDK5R1 immunodetection experiments and how can they be overcome?

Common pitfalls in CDK5R1 immunodetection and their solutions:

This troubleshooting guide addresses the technical challenges specific to CDK5R1 detection, particularly the dynamic nature of p35/p25 processing and the importance of preserving protein modification states.

What strategies can optimize immunofluorescence experiments when investigating CDK5R1 subcellular localization?

Optimizing immunofluorescence for CDK5R1 subcellular localization requires:

• Fixation optimization:

  • Compare multiple fixatives (PFA, methanol, acetone)

  • Test different fixation durations and temperatures

  • For neuronal structures, consider specialized fixatives preserving cytoskeletal elements

  • Evaluate epitope preservation with each method

• Antigen retrieval considerations:

  • Test heat-mediated vs. enzymatic retrieval methods

  • Optimize pH for maximal epitope exposure

  • Balance retrieval intensity with structural preservation

  • Consider no retrieval for certain epitopes/antibodies

• Signal amplification approaches:

  • Tyramide signal amplification for low-abundance detection

  • Quantum dot conjugates for improved signal-to-noise ratio

  • Multi-layer detection systems for weak signals

  • Optimize each amplification step to minimize background

• Co-localization strategies:

  • Select compatible antibody pairs (species, isotypes)

  • Include co-localization controls (known interactors)

  • Employ sophisticated co-localization algorithms beyond simple overlay

  • Use super-resolution techniques for precise spatial relationships

• Quantitative analysis methods:

  • Develop consistent intensity thresholding protocols

  • Employ automated analysis for unbiased quantification

  • Use appropriate statistical tests for spatial distribution

  • Consider 3D analysis for complete subcellular mapping

These approaches enable precise characterization of CDK5R1 subcellular dynamics, which is particularly important given its differential localization in various neuronal compartments and its redistribution in pathological conditions.

How can researchers validate novel CDK5R1 antibodies for research applications?

Comprehensive validation of novel CDK5R1 antibodies requires:

• Epitope characterization:

  • Epitope mapping using peptide arrays

  • Competitive binding assays with defined fragments

  • Structural analysis of epitope accessibility

  • Cross-species conservation assessment

• Specificity validation:

  • Testing in CDK5R1 knockout/knockdown systems

  • Overexpression controls with tagged constructs

  • Cross-reactivity assessment with related proteins (CDK5R2/p39)

  • Immunoprecipitation followed by mass spectrometry

• Application-specific validation:

  • Western blot: Evaluate detection of p35 vs. p25, band specificity

  • IHC/IF: Compare with established antibodies and expression patterns

  • IP: Verify ability to pull down CDK5 complex components

  • ELISA: Determine sensitivity and dynamic range

• Reproducibility assessment:

  • Inter-lot consistency testing

  • Inter-laboratory validation

  • Comparison across multiple experimental systems

  • Documentation of validation data for publication

• Functional correlation:

  • Correlate antibody detection with functional readouts

  • Verify detection of known CDK5R1 variants like p.A108V

  • Confirm expected changes in disease models

These validation steps ensure that novel CDK5R1 antibodies provide reliable results across experimental contexts and applications, increasing research reproducibility and enabling meaningful biological insights.